Annual CFF
$13.67 M
-$2.15 M-13.58%
December 31, 2023
Summary
- As of February 10, 2025, TXG annual cash flow from financing activities is $13.67 million, with the most recent change of -$2.15 million (-13.58%) on December 31, 2023.
- During the last 3 years, TXG annual CFF has fallen by -$455.24 million (-97.08%).
- TXG annual CFF is now -97.08% below its all-time high of $468.91 million, reached on December 31, 2020.
Performance
TXG Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFF
$156.00 K
-$4.45 M-96.61%
September 30, 2024
Summary
- As of February 10, 2025, TXG quarterly cash flow from financing activities is $156.00 thousand, with the most recent change of -$4.45 million (-96.61%) on September 30, 2024.
- Over the past year, TXG quarterly CFF has dropped by -$4.22 million (-96.43%).
- TXG quarterly CFF is now -99.97% below its all-time high of $486.97 million, reached on September 30, 2020.
Performance
TXG Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFF
$12.01 M
-$4.22 M-25.99%
September 30, 2024
Summary
- As of February 10, 2025, TXG TTM cash flow from financing activities is $12.01 million, with the most recent change of -$4.22 million (-25.99%) on September 30, 2024.
- Over the past year, TXG TTM CFF has dropped by -$1.05 million (-8.02%).
- TXG TTM CFF is now -97.67% below its all-time high of $514.38 million, reached on June 30, 2021.
Performance
TXG TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Financing Formula
CFF = Cash Inflows from Financing Activities − Cash Outflows from Financing Activities
TXG Cash From Financing Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -13.6% | -96.4% | -8.0% |
3 y3 years | -97.1% | -98.3% | -66.0% |
5 y5 years | -87.0% | +114.1% | -97.1% |
TXG Cash From Financing Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -61.3% | at low | -98.3% | +104.6% | -66.0% | +20.3% |
5 y | 5-year | -97.1% | at low | -100.0% | +100.5% | -97.7% | +20.3% |
alltime | all time | -97.1% | at low | -100.0% | +100.5% | -97.7% | >+9999.0% |
10x Genomics Cash From Financing History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2024 | - | $156.00 K(-96.6%) | $12.01 M(-26.0%) |
Jun 2024 | - | $4.60 M(+181.0%) | $16.23 M(-13.3%) |
Mar 2024 | - | $1.64 M(-70.8%) | $18.72 M(+37.0%) |
Dec 2023 | $13.67 M(-13.6%) | $5.61 M(+28.3%) | $13.67 M(+4.7%) |
Sep 2023 | - | $4.37 M(-38.4%) | $13.06 M(+21.8%) |
Jun 2023 | - | $7.10 M(-307.9%) | $10.72 M(+7.4%) |
Mar 2023 | - | -$3.41 M(-168.3%) | $9.99 M(-36.9%) |
Dec 2022 | $15.82 M(-55.2%) | $5.00 M(+145.3%) | $15.82 M(-19.8%) |
Sep 2022 | - | $2.04 M(-67.9%) | $19.72 M(-19.1%) |
Jun 2022 | - | $6.36 M(+163.1%) | $24.36 M(-28.8%) |
Mar 2022 | - | $2.42 M(-72.9%) | $34.20 M(-3.1%) |
Dec 2021 | $35.30 M | $8.90 M(+33.2%) | $35.30 M(+3.5%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2021 | - | $6.68 M(-58.7%) | $34.10 M(-93.4%) |
Jun 2021 | - | $16.19 M(+360.3%) | $514.38 M(+1.6%) |
Mar 2021 | - | $3.52 M(-54.3%) | $506.24 M(+8.0%) |
Dec 2020 | $468.91 M(+13.1%) | $7.71 M(-98.4%) | $468.91 M(+1.9%) |
Sep 2020 | - | $486.97 M(+5948.5%) | $460.09 M(+18.3%) |
Jun 2020 | - | $8.05 M(-123.8%) | $388.76 M(+2.3%) |
Mar 2020 | - | -$33.82 M(+2955.0%) | $379.85 M(-8.4%) |
Dec 2019 | $414.59 M(+293.5%) | -$1.11 M(-100.3%) | $414.59 M(-0.3%) |
Sep 2019 | - | $415.64 M(<-9900.0%) | $415.70 M(>+9900.0%) |
Jun 2019 | - | -$864.00 K(-193.6%) | $59.00 K(-93.6%) |
Mar 2019 | - | $923.00 K | $923.00 K |
Dec 2018 | $105.37 M(+411.9%) | - | - |
Dec 2017 | $20.58 M | - | - |
FAQ
- What is 10x Genomics annual cash flow from financing activities?
- What is the all time high annual CFF for 10x Genomics?
- What is 10x Genomics annual CFF year-on-year change?
- What is 10x Genomics quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for 10x Genomics?
- What is 10x Genomics quarterly CFF year-on-year change?
- What is 10x Genomics TTM cash flow from financing activities?
- What is the all time high TTM CFF for 10x Genomics?
- What is 10x Genomics TTM CFF year-on-year change?
What is 10x Genomics annual cash flow from financing activities?
The current annual CFF of TXG is $13.67 M
What is the all time high annual CFF for 10x Genomics?
10x Genomics all-time high annual cash flow from financing activities is $468.91 M
What is 10x Genomics annual CFF year-on-year change?
Over the past year, TXG annual cash flow from financing activities has changed by -$2.15 M (-13.58%)
What is 10x Genomics quarterly cash flow from financing activities?
The current quarterly CFF of TXG is $156.00 K
What is the all time high quarterly CFF for 10x Genomics?
10x Genomics all-time high quarterly cash flow from financing activities is $486.97 M
What is 10x Genomics quarterly CFF year-on-year change?
Over the past year, TXG quarterly cash flow from financing activities has changed by -$4.22 M (-96.43%)
What is 10x Genomics TTM cash flow from financing activities?
The current TTM CFF of TXG is $12.01 M
What is the all time high TTM CFF for 10x Genomics?
10x Genomics all-time high TTM cash flow from financing activities is $514.38 M
What is 10x Genomics TTM CFF year-on-year change?
Over the past year, TXG TTM cash flow from financing activities has changed by -$1.05 M (-8.02%)